Of note, an increased incidence of seborrheic dermatitis was reported as an adverse event accompanying administration of the anti-IL-17A antibody Ixekuzumab (Saeki et al., 2017), and a genetic variant of IL23R was found associated with a decrease in dandruff (Ehm et al., 2017). This evidence concerns the gene IL17A and seborrheic dermatitis.